echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > CTLA-4 fusion protein received FDA priority review qualification to prevent fatal complications of transplant surgery

    CTLA-4 fusion protein received FDA priority review qualification to prevent fatal complications of transplant surgery

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 23, 2021, Bristol-Myers Squibb (BMS) announced that the U.


    Hematopoietic stem cell transplantation is an effective method for the treatment of aggressive leukemia and other hematological malignancies, and is usually the only option for cure


    GvHD occurs when donor T cells recognize the patient's healthy cells as foreign objects and start to attack


    This sBLA application is based on the results of a phase 2 clinical trial of ABA2 and a trial based on real-world data


    Reference materials:

    [1] US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD).


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.